The results for Rem-L alone did not look compelling (barely under p < 0.05 with a population subset selection post-hoc) but the results for Rem-L with dexamethasone looks quite good and should be of good interest to Novartis. Not sure it will be enough for approval though without further trials.
Once again, had Mesoblast excluded older people from the ARDS trial cohort (lots of people on here were worried about this before results were released) then the trial would likely have met its end point and got approved. Comes down to management of these trials and reactivity through the safety board to inclusion criteria etc.
This is at least some good news for holders.
Ann: COVID ARDS Trial Topline 60-Day Results, page-13
-
- There are more pages in this discussion • 1,616 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |